Janux Therapeutics (JANX) Assets Average (2021 - 2026)

Janux Therapeutics (JANX) has reported Assets Average for 6 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average fell 3.91% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (down 3.91% YoY), while the FY2025 annual figure was $1.0 billion, up 43.08% from the prior year.
• Assets Average held at $1.0 billion in Q1 2026 per JANX's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.1 billion in Q1 2025 and bottomed at $347.2 million in Q2 2023.
• Historically, Assets Average has averaged $641.5 million across 5 years, with a median of $534.7 million in 2024.
• Annual changes were most pronounced in 2023 — Assets Average dropped 7.89% — and 2024, when it soared 128.94%.
• Janux Therapeutics' Assets Average stood at $369.9 million in 2022, then increased by 3.72% to $383.6 million in 2023, then jumped by 128.94% to $878.3 million in 2024, then gained by 15.36% to $1.0 billion in 2025, then gained by 0.17% to $1.0 billion in 2026.
• Business Quant data shows JANX's Assets Average at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.